Challenge:

An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs) but not due to earlier indications unacceptable of safety and efficacy. The client had developed an innovative technology capable of eliminating B-cells responsible for producing NAbs from a patient’s repertoire and wanted to identify potential partners interested in resurrecting these assets.

Solution:

We proposed a search for all discontinued antibody, protein, or peptide assets coupled with an intensive literature search for reports of NAbs. A team of Alacrita consultants first met with the client to discuss strategies for identifying assets with evidence of NAbs, given that this information is rarely apparent in commercial pipeline databases.

Once the search approach had been agreed, we shared findings on a rolling basis as  candidate assets were identified. We cataloged our findings in an Excel database that was shared with the client on an ongoing basis and at the end of the engagement. Out of more than 1,000 qualifying programs, 42 were discovered that met the client’s specific search criteria and 174 additional assets were found that required further investigation. 

Explore Our Asset Scouting & In-Licensing Services

Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.